EBCC: Axillary Radiotherapy Without Lymphadenectomy Feasible for Breast Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Carmen Pope, BPharm. Last updated on March 31, 2026.

via HealthDay

TUESDAY, March 31, 2026 -- For patients with breast cancer with limited nodal disease after neoadjuvant therapy, axillary radiotherapy (ART) is as effective as axillary lymphadenectomy (ALND), with fewer cases of lymphedema, according to two studies presented at the annual European Breast Cancer Conference, held from March 25 to 27 in Barcelona, Spain.

Amparo Garcia-Tejedor, M.D., Ph.D., from the Bellvitge University Hospital in Barcelona, Spain, and colleagues examined whether ART without lymphadenectomy can safely replace ALND in patients with limited nodal disease after neoadjuvant therapy in a phase 3 multicenter trial involving patients with cT1 to T4b, cN0 to cN1 breast cancer and one to two positive sentinel lymph nodes. Participants were randomly assigned to ART or ALND (46 and 56, respectively). The researchers observed no axillary recurrences in the ART arm and one (1.8 percent) in the ALND arm. Distant metastases occurred in 4.4 and 5.5 percent, respectively, and there were two deaths in the ALND arm. Comparable two-year disease-free and overall survival rates were seen.

Maria Laplana-Torres, M.D., from the Hospital Clinic of Barcelona in Spain, and colleagues examined the toxicity and quality-of-life profiles of ART versus ALND in the same trial. The researchers found that the mean total RT dose was significantly higher in the ART group versus the ALND group. Acute grade ≥2 skin toxicity occurred in 27.8 and 13.3 percent of patients undergoing ART and ALND, respectively; there were no significant differences in late skin toxicity. The incidence of lymphedema was numerically -- but not statistically significantly -- lower with ART (18.9 versus 26.7 percent). Comparable long-term quality-of-life outcomes were seen between the study arms.

"These results show that axillary radiotherapy may be a safe and less invasive option for some women treated with chemotherapy or hormone therapy before surgery," Laplana-Torres said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-01 01:57

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords